Senti Bio is a clinical-stage biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging its synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. SENTI-202-101 is a first-in-human, multinational, multicenter, phase 1 clinical trial (NCT: 06325748) exploring the safety and efficacy of a novel allogeneic CAR NK cell therapy (SENTI-202) in patients with relapsed/refractory (R/R) CD33+ and/or FLT3+ hematologic malignancies, including acute myeloid leukemia (AML) who have exhausted standard of care options and have a continued unmet need. Early SENTI-202 clinical trial results in adult patients with R/R AML have demonstrated promising results with a generally well-tolerated safety profile that lends itself to outpatient dosing potential. SENTI-202-101 enrolled heavily treated R/R AML patients with poor prognosis. SENTI-202 received both Regenerative Medicine Advance Therapy (RMAT) and Orphan Drug Designation (ODD) designations in 2025. Clinical development plans are underway to launch the Phase 2/pivotal trial in R/R AML and potentially expand into other designations.